Alkermes Announces Positive Topline Results From ENLIGHTEN-Early Phase 3b Study of LYBALVI® in Patients Early in Illness

/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced positive topline results from ENLIGHTEN-Early, a phase 3b study that evaluated the effect of...

Related Keywords

United States ,Massachusetts ,Washington ,Athlone ,Westmeath ,Ireland ,Ohio ,Waltham ,Dublin ,American ,Craig Hopkinson ,Marisa Borgasano ,Ferrari Gozzi ,Sandy Coombs ,Christoph Correll ,American Psychiatric Association ,Alkermes ,National Comorbidity Survey Replication ,Research Development ,Nasdaq ,Exchange Commission ,Alkermes Pharma Ireland ,Alkermes Inc ,Executive Vice President ,Chief Medical Officer ,Molecular Medicine ,Hofstra Northwell School ,Clinical Global Impression ,Early Study ,About Schizophrenia ,Prescribing Information ,Adverse Reactions ,Elderly Patients ,Dementia Related Psychosis ,Boxed Warning ,Severe Opioid Withdrawal ,Physiologically Dependent ,Life Threatening Opioid Overdose ,Malignant Syndrome ,Systemic Symptoms ,Motor Impairment ,Temperature Dysregulation ,Combination Treatment ,Mixed Episodes ,Private Securities Litigation Reform Act ,Annual Report ,Alkermes Pharma Ireland Limited ,Olanzapine Combined With Samidorphan ,Weight Gain ,Week Phase ,Psychological Medicine ,Schizophrenia Spectrum ,Statistical Manual ,American Psychiatric Publishing ,Month Prevalence ,Bipolar Spectrum Disorder ,National Comorbidity Survey ,Arch Gen Psychiatry ,Alkermes Plc ,